Abivax SA (ABVX) Key Metrics
ABVX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · eurosABVX returns How much profit the business earns on the capital it uses.
ABVX financial health Debt, liquidity and how easily interest is covered.
ABVX efficiency & capital use Working capital cycle and where the cash goes.
ABVX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ABVX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ABVX key metrics in euros
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −135.6% | −149.0% | −145.4% | −366.8% | −193.7% | −205.8% | −115.1% | −38.2% | −21.4% | −22.3% |
| Return on invested capital (ROIC) | — | — | — | −282.3% | −165.7% | −115.1% | −84.7% | −47.2% | −34.2% | −43.0% |
| Return on assets (ROA) | −85.2% | −66.2% | −73.4% | −65.7% | −47.0% | −61.0% | −57.9% | −29.3% | −19.6% | −20.9% |
| Return on tangible assets | −60.1% | −97.8% | −48.9% | −120.2% | −55.0% | −95.8% | −156.0% | −71.8% | −51.5% | −50.0% |
| Financial health | ||||||||||
| Total debt | €45.9M | €97.4M | €58.0M | €39.2M | €51.7M | €34.0M | €20.7M | €10.9M | €262,000 | €316,000 |
| Cash & short-term investments | €530.2M | €144.2M | €261.0M | €26.9M | €60.7M | €29.3M | €9.8M | €13.0M | €17.0M | €23.0M |
| Net debt | −€484.3M | −€46.9M | −€202.9M | €12.2M | −€9.0M | €4.7M | €11.0M | −€2.1M | −€16.8M | −€22.7M |
| Debt / equity | 0.10 | 2.40 | 0.30 | 5.45 | 1.99 | 1.90 | 1.12 | 0.31 | 0.01 | 0.01 |
| Debt / assets | 0.08 | 0.47 | 0.18 | 0.52 | 0.47 | 0.48 | 0.40 | 0.20 | 0.00 | 0.01 |
| Current ratio | 8.75 | 1.84 | 3.25 | 0.70 | 2.33 | 1.94 | 1.47 | 2.47 | 3.84 | 7.85 |
| Quick ratio | 8.75 | 1.84 | 3.31 | 0.47 | 2.21 | 1.88 | 1.38 | 2.47 | 3.80 | 7.83 |
| Interest coverage | -8.6 | -13.9 | -9.2 | -9.3 | -11.6 | -18.4 | -21.0 | -40.7 | -456.5 | -434.2 |
| Working capital | €488.0M | €77.8M | €197.9M | −€15.3M | €42.9M | €18.3M | €5.9M | €12.5M | €15.4M | €24.3M |
| Invested capital | −€29.3M | −€6.3M | −€6.9M | €19.4M | €16.9M | €22.6M | €29.6M | €32.6M | €31.4M | €34.0M |
| Tangible asset value | €430.0M | €15.6M | €171.0M | −€17.8M | −€6.2M | −€14.2M | −€13.5M | €2.6M | €16.2M | €24.7M |
| Net current asset value | €421.9M | €6.0M | €154.9M | −€32.2M | −€8.1M | −€15.7M | −€14.9M | €1.6M | €15.2M | €24.0M |
| Capital allocation | ||||||||||
| Dividends paid | €0 | €0 | €0 | €0 | €0 | — | — | — | — | — |
| Capex / revenue | — | 6.0% | 5.7% | 7.0% | 127.0% | 1,425.4% | 47,050.0% | 4,238.9% | 9,790.0% | 567.7% |
| Capex / depreciation | 0.13 | 0.58 | 0.37 | 0.67 | 0.16 | 13.61 | 11.76 | 10.75 | 10.53 | — |
| Stock-based compensation / revenue | — | 187.4% | 177.0% | −25.4% | 2,237.8% | — | — | — | — | — |
| R&D / revenue | — | 1,357.8% | 2,232.8% | 1,053.8% | 129,137.8% | 54,803.2% | 1,450,350.0% | 88,300.0% | 108,460.0% | 12,172.4% |
| SG&A / revenue | — | 351.8% | 608.4% | 163.5% | 15,078.4% | 8,888.9% | 244,600.0% | 23,877.8% | 37,820.0% | 2,801.6% |
| Efficiency | ||||||||||
| Days sales outstanding | — | 587.8 | 1,082.7 | 663.2 | 80,788.3 | 43,507.4 | 1,346,120.0 | 115,786.1 | 154,212.5 | 12,519.2 |
| Days of inventory on hand | — | — | 1,627.5 | 58.2 | 20.5 | 12.3 | 14.9 | — | 3.2 | 2.1 |
| Days payables outstanding | 14,422.9 | — | 16,183.9 | 122.4 | 144.2 | 151.0 | 111.4 | 129.0 | 85.4 | 67.0 |
| Cash conversion cycle (days) | — | — | -13,473.7 | 599.1 | 80,664.6 | 43,368.7 | 1,346,023.6 | 115,657.1 | 154,130.2 | 12,454.3 |
| Receivables turnover | 0.00 | 0.62 | 0.34 | 0.55 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.03 |
| Payables turnover | 0.03 | 0.00 | 0.02 | 2.98 | 2.53 | 2.42 | 3.28 | 2.83 | 4.27 | 5.45 |
| Inventory turnover | — | — | — | 6.27 | 17.77 | 29.70 | 24.47 | — | 115.59 | 173.31 |
| Asset turnover | 0.00 | 0.04 | 0.02 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | €13.1M | €17.4M | €13.7M | €8.3M | €8.2M | €7.5M | €7.4M | €5.7M | €4.2M | €4.4M |
| Average payables | €40.7M | €45.5M | €31.3M | €17.0M | €18.0M | €14.0M | €8.6M | €5.4M | €3.4M | €2.7M |
| Average inventory | — | — | €3.2M | €8.1M | €2.6M | €1.1M | €1.2M | — | €125,500 | €84,500 |
| Intangibles / total assets | 4.3% | 12.2% | 7.7% | 33.1% | 29.4% | 45.0% | 62.0% | 59.2% | 59.5% | 52.8% |
Computed from ABVX's annual financial statements (latest annual report filed March 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in euros; data from EODHD. Averages use the opening and closing balance of each year.
ABVX valuation and financial ratios
Abivax SA earned a return on equity of −135.6% in fiscal 2025. It ended the year with €45.9 million of debt and €530.2 million in cash and short-term investments, a net cash position of €484.3 million.
See the ABVX income statement, the ABVX chart for price history, or the ABVX stock overview for the latest quote and news.
ABVX key metrics FAQ
What is Abivax SA's return on equity?
Abivax SA's return on equity (ROE) was −135.6% in fiscal 2025: net income of -€336.1 million on average shareholders' equity of €247.8 million.
How much debt does Abivax SA have?
Abivax SA had total debt of €45.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.10 and more cash than debt.
Does Abivax SA pay a dividend?
Abivax SA did not pay a dividend in fiscal 2025.
What is Abivax SA's current ratio?
Abivax SA's current ratio was 8.75 at the end of fiscal 2025: current assets were 8.75 times current liabilities.